title: In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?".
authors.forename: Amylynne
authors.initials: A
authors.lastname: Frankel
authors.forename: Abby S
authors.initials: AS
authors.lastname: Van Voorhees
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hsu
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
authors.forename: Bruce F
authors.initials: BF
authors.lastname: Bebo
authors.forename: Alice
authors.initials: A
authors.lastname: Gottlieb
mesh_terms: D016572:Cyclosporine / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D019698:Hepatitis C, Chronic / Q000453:epidemiology*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology*; D012307:Risk Factors
chemical_list: D003879:Dermatologic Agents; D016572:Cyclosporine